BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 15005639)

  • 1. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.
    Le Guellec C; Bourgoin H; Büchler M; Le Meur Y; Lebranchu Y; Marquet P; Paintaud G
    Clin Pharmacokinet; 2004; 43(4):253-66. PubMed ID: 15005639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2011 Dec; 50(12):759-72. PubMed ID: 22087863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.
    de Winter BC; Monchaud C; Prémaud A; Pison C; Kessler R; Reynaud-Gaubert M; Dromer C; Stern M; Guillemain R; Knoop C; Estenne M; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Jan; 51(1):29-39. PubMed ID: 22054177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients.
    Hulin A; Blanchet B; Audard V; Barau C; Furlan V; Durrbach A; Taïeb F; Lang P; Grimbert P; Tod M
    Ther Drug Monit; 2009 Apr; 31(2):224-32. PubMed ID: 19214145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.
    Saint-Marcoux F; Royer B; Debord J; Larosa F; Legrand F; Deconinck E; Kantelip JP; Marquet P
    Clin Pharmacokinet; 2009; 48(10):667-75. PubMed ID: 19743888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy.
    Le Guellec C; Büchler M; Giraudeau B; Le Meur Y; Gakoué JE; Lebranchu Y; Marquet P; Paintaud G
    Eur J Clin Pharmacol; 2002 Jan; 57(11):805-11. PubMed ID: 11868803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
    Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
    Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.
    Prémaud A; Le Meur Y; Debord J; Szelag JC; Rousseau A; Hoizey G; Toupance O; Marquet P
    Ther Drug Monit; 2005 Jun; 27(3):354-61. PubMed ID: 15905807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
    Zahr N; Amoura Z; Debord J; Hulot JS; Saint-Marcoux F; Marquet P; Piette JC; Lechat P
    Clin Pharmacokinet; 2008; 47(4):277-84. PubMed ID: 18336056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.
    Zhao W; Elie V; Baudouin V; Bensman A; André JL; Brochard K; Broux F; Cailliez M; Loirat C; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2010 Apr; 69(4):358-66. PubMed ID: 20406220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.
    Weber LT; Hoecker B; Armstrong VW; Oellerich M; Tönshoff B
    Ther Drug Monit; 2006 Oct; 28(5):623-31. PubMed ID: 17038876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient.
    Eljebari H; Gaies E; Fradj NB; Jebabli N; Salouage I; Trabelsi S; Lakhal M; Klouz A
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1517-24. PubMed ID: 22527344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of abbreviated mycophenolic acid area under the concentration-time curve during early posttransplant period by limited sampling strategy.
    Mohammadpour AH; Nazemian F; Abtahi B; Naghibi M; Gholami K; Rezaee S; Nazari MR; Rajabi O
    Transplant Proc; 2008 Dec; 40(10):3668-72. PubMed ID: 19100462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.